Project

Determination of HPV E6 16&18

Goal: Cost effective diagnosis for cervical cancer patient.

Updates
0 new
0
Recommendations
0 new
0
Followers
0 new
4
Reads
1 new
19

Project log

Umme Shahera
added a research item
Objective The Onco E6™ Cervical Test, based on detection of the E6 oncoprotein of HPV 16 and 18 genotypes is evaluated as a screen for the early detection cervical neoplasia in resource-limited countries. Methods This prospective study from June 2018 to June 2019 evaluated 235 women aged 21–65 years, who came to Gynaecological Oncology Outpatient Department by VIA, cytology, E6 oncoprotein test and by colposcopy. Screen-positive women by any of the tests or women with suspicious findings were further evaluated by biopsy at colposcopy. The McNemar test was used to compare the performance of E6 oncoprotein test with other screening tests. Results The E6 oncoprotein positivity rate was 6.8% (n = 16) with 81.25% HPV 16 positive and 18.75% HPV 18 positive. Among VIA positive cases (n = 100), E6 oncoprotein was positive in 9% (p < .001). In histopathology confirmed chronic cervicitis, CIN I, CIN II, CIN III and invasive cervical cancer, E6 test was positive for 2.8%, 4.7%, 25%, 50% and 100% respectively. E6 oncoprotein test had the highest specificity and Positive Predictive Value (PPV; 97% and 75%) compared to VIA (42% and 18%), cytology (95% and 46%) and colposcopy (94% and 59%). Sensitivity of the E6 oncoprotein test for detection of CIN3+ was significantly higher than that of cytology (52% VS 25%) but lower than that of VIA (52% VS 74%). Conclusions The HPV E6 oncoprotein test is highly specific and is an effective triage test to reduce colposcopy referrals for the large number of false positive test outcomes seen with VIA.
Umme Shahera
added 2 research items
PurposeThis research was carried out with the intention to see the detection rate of HPV-16/18 E6 oncoprotein expression in different categories of cervical neoplasia and to find out its association with increasing neoplastic state, using lateral flow test “Onco E6 Cervical Test” designed for low-resource settings.MethodsA cross-sectional study was conducted at Gynecologic Oncology Outpatient Department (OPD) of Bangabandhu Sheikh Mujib Medical University (BSMMU), Dhaka, Bangladesh, from May 2018 to April 2019. Histopathologically diagnosed CIN I, CIN II, CIN III, and cervical cancer cases of age 21–70 years who were compliant to allow cervical swab collection for E6 oncoprotein test were selected by purposive sampling.ResultsE6 oncoprotein expression was 4.44% (2/45), 28.57% (4/14), 50% (2/4), and 77.78% (28/36) for CIN I, CIN II, CIN III, and cervical cancer cases, respectively. Thirty-six women of total 99 (N = 99) study participants were found E6 positive (detection rate 36.36%). Type distribution showed 83.33% (30/36) type 16, 13.89% (5/36) type 18, and 2.78% (1/36) co-infection with types 16 and 18. Considering CIN I the reference category, E6 oncoprotein expression was found associated with CIN II (OR = 6.95, p = 0.052), significantly associated with CIN III (OR = 18.10, p = 0.026), and highly significantly associated with cervical cancer (OR = 43.57, p < 0.001).Conclusion Association of E6 oncoprotein expression is significant for CIN III and highly significant for cervical cancer. The presence of E6 oncoprotein expression in CIN lesions can identify true cancer precursors with risk of cancer development in the future and can be utilized in cancer screening program.
Purpose This research was carried out with the intention to see the detection rate of HPV-16/18 E6 oncoprotein expression in different categories of cervical neoplasia and to find out its association with increasing neoplastic state, using lateral flow test ''Onco E6 Cervical Test'' designed for low-resource settings. Methods A cross-sectional study was conducted at Gynecologic Oncology Outpatient Department (OPD) of Bangabandhu Sheikh Mujib Medical University (BSMMU), Dhaka, Bangladesh, from May 2018 to April 2019. Histopathologically diagnosed CIN I, CIN II, CIN III, and cervical cancer cases of age 21-70 years who were compliant to allow cervical swab collection for E6 oncoprotein test were selected by purposive sampling. Results E6 oncoprotein expression was 4.44% (2/45), 28.57% (4/14), 50% (2/4), and 77.78% (28/36) for CIN I, CIN II, CIN III, and cervical cancer cases, respectively. Thirty-six women of total 99 (N = 99) study participants were found E6 positive (detection rate 36.36%). Type distribution showed 83.33% (30/36) type 16, 13.89% (5/36) type 18, and 2.78% (1/ 36) co-infection with types 16 and 18. Considering CIN I the reference category, E6 oncoprotein expression was found associated with CIN II (OR = 6.95, p = 0.052), significantly associated with CIN III (OR = 18.10, p = 0.026), and highly significantly associated with cervical cancer (OR = 43.57, p \ 0.001). Conclusion Association of E6 oncoprotein expression is significant for CIN III and highly significant for cervical cancer. The presence of E6 oncoprotein expression in CIN lesions can identify true cancer precursors with risk of cancer development in the future and can be utilized in cancer screening program.
Umme Shahera
added a project goal
Cost effective diagnosis for cervical cancer patient.